Ignite Creation Date:
2025-12-24 @ 5:49 PM
Ignite Modification Date:
2025-12-29 @ 6:01 PM
Study NCT ID:
NCT01377168
Status:
COMPLETED
Last Update Posted:
2017-06-16
First Post:
2011-06-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Naltrexone for Medication Compliance Among HIV-infected Men With Alcohol Use Disorder
Sponsor:
Fred Hutchinson Cancer Center
Organization:
Study Overview
Official Title:
Oral Naltrexone for Improved Medication Compliance Among HIV-infected Men With Alcohol Use Disorder
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will recruit 159 HIV-infected men with alcohol use disorders (AUDs). Men will be randomized to receive either oral naltrexone for the treatment of alcohol use disorder or placebo. Men with acute, recent or established HIV infection will receive antiretroviral treatment (ART) and be randomized to oral naltrexone or placebo. The purpose of this study is to see whether use of oral naltrexone improves medication compliance, and therefore HIV viral load suppression, among men with alcohol use disorder. The study will also assess the impact of oral naltrexone on alcohol use behaviors in this population.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: